MedinCell SA · EURONEXT:MEDCL
MedinCell SA — Corporate Update (April 2020)
8 slides from MedinCell SA's corporate update, Apr 23, 2020
Slide 1: Videoconference: Adapt and overcome to the Covid-19 crisis
Videoconference Adapt and overcome to the Covid-19 crisis April 23, 2020
Slide 2: Product portfolio progression: clinical stage
Product portfolio progression Clinical stage With Teva Pharmaceuticals • mdc-IRM (maintenance treatment of schizophrenia) • mdc-TJK (antipsychotic) With AIC • mdc-CWM (post-operative pain and inflammation) •
Slide 3: Product portfolio progression: next potential candidates
Product portfolio progression Next potential candidates for clinical development With the Bill & Melinda Gates Foundation • mdc-WWM (contraception) Internal products internes • mdc-GRT (Organ transplant) • mdc-NVA (Pain) • mdc-KPT (Animal Health / Pain) •
Slide 4: Product portfolio progression: other recent developments
Product portfolio progression Other recent developments • mdc-CMV (surgical anaesthesia and 3 days of postoperative analgesia) With Unitaid • $ 6,4 millions grant for a a 3-month acting injectable ivermectin to neutralize the transmission vector of Malaria With the Bill & Melinda Gates Foundation •
Slide 5: Prevention: the third path to fight Covid-19
The third path to fight Covid-19 Prevention •
Slide 6: Actions taken in response to the Covid-19 crisis
Actions taken in response to the Covid-19 crisis •
Slide 7: Q/A
Q/A You can send your questions by using the chat on the right of your screen
Slide 8: Thank you
Thank you MedinCell 3, rue des frères Lumière www.medincell.com 34830 Jacou • France